Regeneron says its antibody treatment may not be as effective against Omicron, but testing is underway.

By BY BENJAMIN MUELLER from NYT Health The company said that analyses and modeling of mutations in the variant suggest that they may weaken the effect of the treatment, but that studies using Omicron’s full sequences are incomplete. https://ift.tt/3EaJuoT